InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,214.72
(
0.01%
)
US TECH 100
17,679.20
(
0.22%
)
Dow Jones
39,469.68
(
0.21%
)
Brent Oil
82.75
(
-1.43%
)
Bitcoin
60,773.97
(
-3.61%
)
Post# of 251785
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 829
Posts 119608
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: None

Wednesday, 06/28/2017 9:21:17 AM

Wednesday, June 28, 2017 9:21:17 AM

Post# of 251785
MRSN IPOs 5.75M* shares @$15.00:

http://www.businesswire.com/news/home/20170627006566/en/Mersana-Therapeutics-Announces-Pricing-Initial-Public-Offering

Mersana Therapeutics is a clinical-stage biotechnology company with highly differentiated and proprietary ADC platforms that allow for significantly higher drug loads, with the potential to provide greater efficacy while simultaneously increasing tolerability.

…Our lead product candidate, XMT-1522, is in Phase I clinical trials. We expect that our second product candidate, XMT-1536, will be entering clinical trials in early 2018. In addition, our partners are advancing their pipeline of ADCs using our platform.

*Assuming exercise of underwriter’s option.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up